Abstract
Increasing Lifestyle Disorders Call for New Genre of Biologic Therapies
The need to offer newer treatment therapies is critical with
lifestyle-related maladies such as obesity, type-II diabetes, and cardiovascular
disorders on the rise. An increasing number of people suffering from lethal
diseases such as cancer, AIDS, and auto-immune disorders and an ageing U.S. baby
boomer population also require medical attention. These unmet healthcare
requirements act as a major driver for the development of biologics.
This Frost & Sullivan research examines the ongoing efforts to develop
new biologic therapies. It offers detailed analysis of five path-breaking
technologies with products under advanced clinical trials: monoclonal
antibodies, gene therapy, cancer vaccines, cellular therapy, and cytokines. The
comprehensive coverage is likely to help pharmaceutical and biotech companies
formulate strategies for growth.
Robust Pipeline of Biologics Drives Dynamic Growth in the Biotech Industry
More than 370 drugs are undergoing clinical trials according to a survey
conducted by the Pharmaceutical Research and Manufacturers of America (PhRMA).
"The new drugs can address a plethora of serious medical conditions such as
AIDS, cancer, diabetes and related conditions, autoimmune, blood disorders,
digestive disorders, and cardiovascular disorders among others," says the
analyst of this research service.
Exciting developments are taking place in the technologies of angiogenesis
inhibitors, antisense, cellular therapy, colony stimulating factor, gene
therapy, growth factors, and human growth hormones. Other areas of therapy
poised for growth are immune-based therapy, cytokines, monoclonal antibodies,
and recombinant human proteins.
Impending Expiry of Drug Patents Prompts New Biologics Drug Development
By 2006, patents for many pharmaceutical and biologic products will expire
and competition from generics would be imminent. There is likely to be a
decrease in sales and profits, compelling large pharmaceutical and biotech
companies to develop new products that can contribute to the revenue stream.
"The many new monoclonal antibodies and new technology drugs such as
cancer vaccines and gene therapy, on the verge of approval, will provide the
needed momentum to the biotech industry to counter this challenge in the coming
years," concludes the analyst.
View Cart
